 | Up a level |
2022
Geyer, C. E., Jr., Garber, J. E., Gelber, R. D., Yothers, G., Taboada, M., Ross, L., Rastogi, P., Cui, K., Arahmani, A., Aktan, G., Armstrong, A. C., Arnedos, M., Balmana, J., Bergh, J., Bliss, J., Delaloge, S., Domchek, S. M., Eisen, A., Elsafy, F., Fein, L. E., Fielding, A., Ford, J. M., Friedman, S., Gelmon, K. A., Gianni, L., Gnant, M., Hollingsworth, S. J., Im, S-A, Jager, A., Lakhani, S. R., Janni, W., Linderholm, B., Liu, T-W, Loman, N., Korde, L., Loibl, S., Lucas, P. C., Marme, F., de Duenas, E. Martinez, McConnell, R., Phillips, K-A, Piccart, M., Rossi, G., Schmutzler, R., Senkus, E., Shao, Z., Sharma, P., Singer, C. F., Spanic, T., Stickeler, E., Toi, M., Traina, T. A., Viale, G., Zoppoli, G., Park, Y. H., Yerushalmi, R., Yang, H., Pang, D., Jung, K. H., Mailliez, A., Fan, Z., Tennevet, I, Zhang, J., Nagy, T., Sonke, G. S., Sun, Q., Parton, M., Colleoni, M. A., Schmidt, M., Brufsky, A. M., Razaq, W., Kaufman, B., Cameron, D., Campbell, C., Tutt, A. N. J. and Johannsson, O. Th (2022). Overall survival in the OlympiA phase Ill trial of adjuvant olaparib in patients with germime pathogenic variants in BRCA1/2 and high-risk, early breast cancer. Ann. Oncol., 33 (12). S. 1250 - 1269. AMSTERDAM: ELSEVIER. ISSN 1569-8041
Huober, J., Janni, W., Untch, M., Blohmer, J-U., Zahm, D-M., Hanusch, C., Jackisch, C., Heinrich, G., Schneeweiss, A., Denkert, C., Link, T., Rhiem, K. E., Furlanetto, J., Solbach, C., Klare, P., Nekljudova, V., Filmann, N. and Loibl, S. (2022). Long-term survival of a randomised, open-label, phase II study comparing the efficacy and safety of cabazitaxel versus weekly paclitaxel given as neoadjuvant treatment in patients with operable triple-negative or luminal B/HER2-negative breast cancer (GENEVIEVE). Ann. Oncol., 33 (7). S. S615 - 1. AMSTERDAM: ELSEVIER. ISSN 1569-8041
Laakmann, E., Riecke, K., Neunhoeffer, T., Park-Simon, T-W., Weide, R., Polasik, A., Schmidt, M., Puppe, J., Fasching, P. A., Hesse, T., Decker, T., Denkert, C., Fehm, T. N., Nekljudova, V., Rey, J., Loibl, S., Mueller, V. and Witzel, I. (2022). Long-term survival of HER2-positive breast cancer patients with brain metastases: Subanalysis of the BMBC registry. Ann. Oncol., 33 (7). S. S660 - 1. AMSTERDAM: ELSEVIER. ISSN 1569-8041
Laakmann, E., Riecke, K., Neunhoeffer, T., Park-Simon, T-WP, Weide, R., Polasik, A., Schmidt, M., Puppe, J., Fasching, P. A., Hesse, T., Decker, T., Denkert, C., Fehm, T., Nekljudova, V, Rey, J., Loibl, S., Mueller, V and Witzel, I (2022). Long-term survival of HER2-positive breast cancer patients with brain metastases: subanalysis of the BMBC Registry. Geburtshilfe Frauenheilkd., 82 (10). S. E113 - 1. STUTTGART: GEORG THIEME VERLAG KG. ISSN 1438-8804
Laakmann, E., Witzel, I, Neunhoeffer, T., Park-Simon, T-W, Weide, R., Riecke, K., Polasik, A., Schmidt, M., Puppe, J., Mundhenke, C., Lubbe, K., Hesse, T., Thill, M., Zahm, D-M, Denkert, C., Fehm, T., Nekljudova, V, Rey, J., Loibl, S. and Mueller, V (2022). Characteristics of patients with brain metastases from human epidermal growth factor receptor 2-positive breast cancer: subanalysis of Brain Metastases in Breast Cancer Registry. ESMO Open, 7 (3). AMSTERDAM: ELSEVIER. ISSN 2059-7029
Loibl, S., Reinisch, M., Denkert, C., Fasching, P. A., Seiler, S., Link, T., Hanusch, C., Bjelic-Radisic, V., Schneeweiss, A., Huober, J., Jackisch, C., Rhiem, K. E., Untch, M., Solbach, C., Blohmer, J-U., Buechele, T., Nekljudova, V. and Loi, S. (2022). A randomized, open-label, phase II trial comparing neoadjuvant trastuzumab, pertuzumab and endocrine therapy +/- the PI3K inhibitor inavolisib in patients (pts) with HER2+/HR+, PIK3CA mutant early breast cancer (BC)-GeparPiPPa. Ann. Oncol., 33 (7). S. S627 - 1. AMSTERDAM: ELSEVIER. ISSN 1569-8041
Loibl, S., Schneeweiss, A., Huober, J., Braun, M., Rey, J., Blohmer, J. U., Furlanetto, J., Zahm, D. M., Hanusch, C., Thomalla, J., Jackisch, C., Staib, P., Link, T., Rhiem, K., Solbach, C., Fasching, P. A., Nekljudova, V., Denkert, C. and Untch, M. (2022). Neoadjuvant durvalumab improves survival in early triple-negative breast cancer independent of pathological complete response. Ann. Oncol., 33 (11). S. 1149 - 1159. AMSTERDAM: ELSEVIER. ISSN 1569-8041
Loibl, S., Untch, M., Burchardi, N., Huober, J., Sinn, B. V., Blohmer, J. -U., Grischke, E. -M., Furlanetto, J., Tesch, H., Hanusch, C., Engels, K., Rezai, M., Jackisch, C., Schmitt, W. D., von Minckwitz, G., Thomalla, J., Kuemmel, S., Rautenberg, B., Fasching, P. A., Weber, K., Rhiem, K., Denkert, C. and Schneeweiss, A. (2022). A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study (vol 30, pg 1279, 2019). Ann. Oncol., 33 (7). S. 743 - 745. AMSTERDAM: ELSEVIER. ISSN 1569-8041
Reinisch, M., Blohmer, J-U., Link, T., Just, M., Untch, M., Stoetzer, O., Fasching, P. A., Schneeweiss, A., Wimberger, P., Seiler, S., Huober, J., Thill, M., Jackisch, C., Rhiem, K., Solbach, C., Hanusch, C., Denkert, C., Engels, K., Nekljudova, V. and Loibl, S. (2022). Patient quality of life (QoL) from the GeparX trial on the addition of denosumab (Dmab) added to two different nab-paclitaxel (nP) regimens as neoadjuvant chemotherapy (NACT) in primary breast cancer (BC). Ann. Oncol., 33. S. S166 - 2. AMSTERDAM: ELSEVIER. ISSN 1569-8041
Riecke, K., Laakmann, E., Neunhoffer, T., Park-Simon, T-W., Weide, R., Schmidt, M., Polasik, A., Puppe, J., Mundhenke, C., Luebbe, K., Hesse, T., Thill, M., Zahm, D-M., Denkert, C., Fehm, T., Nekljudova, V., Rey, J., Loibl, S., Mueller, V. and Witzel, I. (2022). Long-term survival of breast cancer patients with brain metastases: Subanalysis of the BMBC registry. Ann. Oncol., 33. S. S202 - 2. AMSTERDAM: ELSEVIER. ISSN 1569-8041
2021
Fasching, P. A., Link, T., Hauke, J., Seither, F., Jackisch, C., Klare, P., Schmatloch, S., Hanusch, C., Huober, J., Stefek, A., Seiler, S., Schmitt, W. D., Uleer, C., Doering, G., Rhiem, K., Schneeweiss, A., Engels, K., Denkert, C., Schmutzler, R. K., Hahnen, E., Untch, M., Burchardi, N., Blohmer, J-U and Loibl, S. (2021). Neoadjuvant paclitaxel/olaparib in comparison to paclitaxel/carboplatinum in patients with HER2-negative breast cancer and homologous recombination deficiency (GeparOLA study). Ann. Oncol., 32 (1). S. 49 - 58. AMSTERDAM: ELSEVIER. ISSN 1569-8041
Laakmann, E., Witzel, I., Neunhoeffer, T., Park-Simon, T-W., Weide, R., Riecke, K., Polasik, A., Schmidt, M., Puppe, J., Mundhenke, C., Luebbe, K., Hesse, T., Thill, M., Zahm, D-M., Denkert, C., Fehm, T., Nekljudova, V., Rey, J., Loibl, S. and Mueller, V. (2021). Characteristics of patients with brain metastases from HER2-positive breast cancer. Ann. Oncol., 32. S. S63 - 2. AMSTERDAM: ELSEVIER. ISSN 1569-8041
Labidi-Galy, S. I., Schneeweiss, A., Sinn, H. P., Blohmer, J-U., Romanens, L., Zahm, D-M., Huober, J., Dohnal, D., Link, T., Hanusch, C., Jackisch, C., Fasching, P. A., Solbach, C., Rhiem, K. E., Denkert, C., Weber, K. E., Lederer, B., Untch, M., Loibl, S. and Furlanetto, J. (2021). Baseline menopausal status, Ki-67 and stromal tumour-infiltrating lymphocytes (TILs) and association with outcome in triple-negative breast cancer (TNBC): Exploratory analysis in GeparSixto. Ann. Oncol., 32. S. S49 - 2. AMSTERDAM: ELSEVIER. ISSN 1569-8041
Llop-Guevara, A., Loibl, S., Villacampa, G., Vladimirova, V., Schneeweiss, A., Karn, T., Zahm, D. -m., Herencia-Ropero, A., Jank, P., van Mackelenbergh, M., Fasching, P. A., Marme, F., Stickeler, E., Schem, C., Dienstmann, R., Florian, S., Nekljudova, V., Balmana, J., Hahnen, E., Denkert, C. and Serra, V. (2021). Association of RAD51 with homologous recombination deficiency (HRD) and clinical outcomes in untreated triple-negative breast cancer (TNBC): analysis of the GeparSixto randomized clinical trial. Ann. Oncol., 32 (12). S. 1590 - 1597. AMSTERDAM: ELSEVIER. ISSN 1569-8041
Marme, F., Hanusch, C., Furlanetto, J., Denkert, C., Link, T., Untch, M., Blohmer, J-U., Jackisch, C., Reinisch, M., Rhiem, K. E., Schneeweiss, A., Solbach, C., Schoellhorn, L., Fasching, P. A., Rey, J. and Loibl, S. (2021). Phase III post-neoadjuvant study evaluating sacituzumab govitecan (SG), an antibody drug conjugate in primary HER2-negative breast cancer patients with high relapse risk after standard neoadjuvant treatment: SASCIA. Ann. Oncol., 32. S. S443 - 2. AMSTERDAM: ELSEVIER. ISSN 1569-8041
2020
Hauke, J., Ernst, C., Fasching, P. A., Jackisch, C., Seither, F., Klare, P., Rhiem, K. E., Schmatloch, S., Huober, J., Stefek, A., Seiler, S., Uleer, C., Doering, G., Schneeweiss, A., Denkert, C., Untch, M., Blohmer, J-U., Schmutzler, R. K., Loibl, S. and Hahnen, E. (2020). Germline mutation status and therapy response in patients with homologous recombination deficient, HER2-negative early breast cancer: Results of the GeparOLA study (NCT02789332). Ann. Oncol., 31. S. S313 - 1. AMSTERDAM: ELSEVIER. ISSN 1569-8041
Link, T., Blohmer, J-U., Just, M., Untch, M., Stoetzer, O., Fasching, P. A., Schneeweiss, A., Wimberger, P., Seiler, S., Huober, J., Schmitt, W. D., Jackisch, C., Rhiem, K. E., Hanusch, C., Denkert, C., Sinn, B. V., Engels, K., Nekljudova, V. and Loibl, S. (2020). GeparX: Denosumab (Dmab) as add-on to different regimen of nab-paclitaxel (nP)-anthracycline based neoadjuvant chemotherapy (NACT) in early breast cancer (BC): Subgroup analyses by RANK expression and HR status. Ann. Oncol., 31. S. S308 - 2. AMSTERDAM: ELSEVIER. ISSN 1569-8041
Schneeweiss, A., Moebus, V., Tesch, H., Klare, P., Denkert, C., Kast, K., Hanusch, C., Link, T., Untch, M., Jackisch, C., Blohmer, J-U., Fasching, P. A., Solbach, C., Huober, J., Rhiem, K. E., Nekljudova, V., Luebbe, K. and Loibl, S. (2020). Survival analysis of the randomized phase III GeparOcto trial comparing neoadjuvant chemotherapy (NACT) of iddEPC versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triplenegative breast cancer, TNBC) (PM(Cb)) for patients (pts) with highrisk early breast cancer (BC). Ann. Oncol., 31. S. S303 - 2. AMSTERDAM: ELSEVIER. ISSN 1569-8041
2019
Loibl, S., Untch, M., Burchardi, N., Huober, J., Sinn, B., V, Blohmer, J-U, Grischke, E-M, Furlanetto, J., Tesch, H., Hanusch, C., Engels, K., Rezai, M., Jackisch, C., Schmitt, W. D., von Minckwitz, G., Thomalla, J., Kuemmel, S., Rautenberg, B., Fasching, P. A., Weber, K., Rhiem, K., Denkert, C. and Schneeweiss, A. (2019). A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study. Ann. Oncol., 30 (8). S. 1279 - 1289. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041
2018
Loibl, S., Weber, K. E., Timms, K. M., Elkin, E. P., Hahnen, E., Fasching, P. A., Lederer, B., Denkert, C., Schneeweiss, A., Braun, S., Salat, C. T., Rezai, M., Blohmer, J. U., Zahm, D. M., Jackisch, C., Gerber, B., Klare, P., Kuemmel, S., Schem, C., Paepke, S., Schmutzler, R., Rhiem, K., Penn, S., Reid, J., Nekljudova, V., Hartman, A-R, von Minckwitz, G. and Untch, M. (2018). Survival analysis of carboplatin added to an anthracycline/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response-final results from GeparSixto. Ann. Oncol., 29 (12). S. 2341 - 2348. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041
Pohl, E., Schneeweiss, A., Hauke, J., Moebus, V., Furlanetto, J., Denkert, C., Fasching, P. A., Hanusch, C., Tesch, H., Weber-Lassalle, N., Mueller, V., Rhiem, K., Untch, M., Luebbe, K., Lederer, B., Jackisch, C., Nekljudova, V., Schmutzler, R. K., Hahnen, E. and Loibl, S. (2018). Germline mutation status and therapy response in patients with triple-negative breast cancer (TNBC): Results of the GeparOcto study. Ann. Oncol., 29. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041
Untch, M., Jackisch, C., Schneeweiss, A., Schmatloch, S., Aktas, B., Denkert, C., Schem, C., Wiebringhaus, H., Kuemmel, S., Rhiem, K., Warm, M., Fasching, P. A., Just, M., Hanusch, C., Hackmann, J., Blohmer, J-U., Furlanetto, J., Nekljudova, V., von Minckwitz, G. and Loibl, S. (2018). Impact of nab-paclitaxel dose reduction on survival of the randomized phase III GeparSepto trial comparing neoadjuvant chemotherapy of weekly nab-paclitaxel (nP) with solvent-based paclitaxel (P) followed by anthracycline/cyclophosphamide for patients with early breast cancer (BC). Ann. Oncol., 29. S. 60 - 61. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041
2017
von Minckwitz, G., Timms, K., Untch, M., Elkin, E. P., Hahnen, E., Fasching, P. A., Schneeweiss, A., Salat, C. T., Rezai, M., Blohmer, J-U, Zahm, D-M, Jackisch, C., Gerber, B., Klare, P., Kummel, S., Paepke, S., Schmutzler, R., Chau, S., Reid, J., Hartman, A-R, Nekljudova, V., Weber, K. E. and Loibl, S. (2017). Homologous repair deficiency (HRD) as measure to predict the effect of carboplatin on survival in the neoadjuvant phase II trial GeparSixto in triple-negative early breast cancer. Cancer Res., 77. PHILADELPHIA: AMER ASSOC CANCER RESEARCH. ISSN 1538-7445
2011
Moebus, V., Diel, I. J., Harbeck, N., Elling, D., Jackisch, C., Thomssen, C., Untch, M., Conrad, B., Schneeweiss, A., Kreienberg, R., Huober, J., Mueller, V., Lueck, H-J, Bauerfeind, I., Loibl, S., Nekljudova, V. and von Minckwitz, G. (2011). GAIN Study: A Phase III Trial To Compare ETC vs. EC-TX and Ibandronate vs. Observation in Patients with Node-Positive Primary Breast Cancer 1st Interim Efficacy Analysis. Cancer Res., 71. PHILADELPHIA: AMER ASSOC CANCER RESEARCH. ISSN 1538-7445
von Minckwitz, G., Kaufmann, M., Kuemmel, S., Fasching, P. A., Eiermann, W., Blohmer, J. U., Costa, S. D., Hilfrich, J., Jackisch, C., Gerber, B., Barinoff, J., Huober, J., Hanusch, C., Konecny, G., Fett, W., Stickeler, E., Harbeck, N., Mehta, K., Loibl, S. and Untch, M. (2011). Local Recurrence Risk in 6377 Patients with Early Breast Cancer Receiving Neoadjuvant Anthracycline-Taxane plus /-Trastuzumab Containing Chemotherapy. Cancer Res., 71. PHILADELPHIA: AMER ASSOC CANCER RESEARCH. ISSN 1538-7445
2010
Untch, M., Fasching, P. A., Konecny, G. E., Hasmueller, S., Lebeau, A., Kreienberg, R., Camara, O., Mueller, V., du Bois, A., Kuehn, T., Stickeler, E., Harbeck, N., Hoess, C., Kahlert, S., Beck, T., Fett, W., Mehta, K., von Minckwitz, G. and Loibl, S. (2010). Pathological Complete Response after Neoadjuvant Chemotherapy plus Trastuzumab Treatment Predicts Survival and Detects a Patient Subgroup at High Need for Improvement of Anti-HER2 Therapy. Three Year Median Follow-Up Data of the TECHNO Trial. Cancer Res., 70. PHILADELPHIA: AMER ASSOC CANCER RESEARCH. ISSN 1538-7445